Healthcare provider profile · identity verified

Sidney Mitchell, MD

Family Practice · WATSONVILLE, CA · NPI 1518027630

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	447	123
Atorvastatin Calcium	Atorvastatin Calcium	330	82
Eliquis	Apixaban	313	35
Spironolactone	Spironolactone	298	82
Amlodipine Besylate	Amlodipine Besylate	286	84
Furosemide	Furosemide	269	72
Quetiapine Fumarate	Quetiapine Fumarate	227	51
Tramadol Hcl	Tramadol Hcl	145	55
Metoprolol Tartrate	Metoprolol Tartrate	144	29
Levothyroxine Sodium	Levothyroxine Sodium	120	35
Metoprolol Succinate	Metoprolol Succinate	104	36
Tamsulosin Hcl	Tamsulosin Hcl	95	27
Trazodone Hcl	Trazodone Hcl	83	19
Cephalexin	Cephalexin	82	32
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	72	18
Famotidine	Famotidine	69	22
Metformin Hcl	Metformin Hcl	69	16
Pioglitazone Hcl	Pioglitazone Hcl	66	17
Carvedilol	Carvedilol	65	14
Xarelto	Rivaroxaban	64	suppressed
Divalproex Sodium	Divalproex Sodium	60	11
Levetiracetam	Levetiracetam	58	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	54	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	53	suppressed
Clopidogrel	Clopidogrel Bisulfate	51	suppressed
Duloxetine Hcl	Duloxetine Hcl	48	suppressed
Lisinopril	Lisinopril	48	17
Risperidone	Risperidone	45	suppressed
Allopurinol	Allopurinol	42	suppressed
Olanzapine	Olanzapine	38	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	35	suppressed
Glipizide Er	Glipizide	35	15
Memantine Hcl	Memantine Hcl	35	suppressed
Mirtazapine	Mirtazapine	35	suppressed
Diclofenac Sodium	Diclofenac Sodium	33	12
Donepezil Hcl	Donepezil Hcl	32	suppressed
Sertraline Hcl	Sertraline Hcl	32	suppressed
Aripiprazole	Aripiprazole	30	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	15
Glipizide	Glipizide	26	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	15
Lactulose	Lactulose	21	suppressed
Nystatin	Nystatin	21	11
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	13
Clonidine Hcl	Clonidine Hcl	18	suppressed
Lamotrigine	Lamotrigine	18	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	18	12
Alendronate Sodium	Alendronate Sodium	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Morphine Sulfate	Morphine Sulfate	17	15
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	16	suppressed
Divalproex Sodium Er	Divalproex Sodium	16	suppressed
Entacapone	Entacapone	16	suppressed
Lumigan	Bimatoprost	16	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	16	suppressed
Digoxin	Digoxin	15	suppressed
Dilantin	Phenytoin Sodium Extended	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Finasteride	Finasteride	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Megestrol Acetate	Megestrol Acetate	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Prednisone	Prednisone	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Atenolol	Atenolol	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error